What are the approved stem cell therapy indications in Japan according to the Japan Medical Association?
As of 2025, the Japan Medical Association (JMA) does not officially publish a single, standalone list of "approved stem cell therapy indications" that applies uniformly across all clinics and hospitals. Instead, the regulatory framework in Japan operates under a two-track system: the Pharmaceuticals and Medical Devices Agency (PMDA) oversees therapies approved as medical products, while the Ministry of Health, Labour and Welfare (MHLW) and local governments regulate clinic-based treatments under the Act on Safety of Regenerative Medicine (ASRM), enacted in 2014. The JMA provides guidance and ethical oversight, but the actual approval of indications comes from these regulatory bodies. For a comprehensive breakdown of what is currently allowed, you can find detailed stem cell therapy indications in Japan information from Japan Medical sources compiled by specialized clinics and researchers.
The PMDA has approved a handful of stem cell-based products as drugs or medical devices. For instance, JACC (Japanese Adult Cardiac Stem Cells) was conditionally approved for acute myocardial infarction in 2015, but it was later withdrawn from the market in 2020 due to low demand and reimbursement issues. Temcell, a mesenchymal stem cell (MSC) product from human bone marrow, is approved for acute graft-versus-host disease (aGVHD) in children and adults after hematopoietic stem cell transplantation. Stemirac, an autologous bone marrow-derived MSC product, received conditional approval in 2018 for spinal cord injury (SCI) within 2 to 4 weeks post-injury. HeartSheet, a myoblast sheet, is approved for severe heart failure, but it is not a stem cell product in the strict sense—it uses skeletal muscle cells. Alofisel (darvadstrocel), an allogeneic adipose-derived MSC product, is approved for complex perianal fistulas in Crohn's disease. These are the only PMDA-approved stem cell therapies as of 2025, and they cover a very narrow set of indications.
Under the ASRM, clinics can offer unapproved stem cell therapies as long as they submit a plan to the MHLW and receive approval from a Certified Special Committee for Regenerative Medicine. This committee, often composed of JMA members, evaluates safety and basic efficacy. As of 2023, over 3,000 plans have been submitted, covering a wide range of conditions. The most common indications include knee osteoarthritis, chronic pain, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, type 1 diabetes, liver cirrhosis, kidney failure, erectile dysfunction, female infertility, hair loss, skin rejuvenation, and autoimmune diseases like rheumatoid arthritis and multiple sclerosis. However, it is crucial to understand that these are not "approved" in the same sense as PMDA-approved drugs. They are allowed under a conditional, risk-based framework, and the JMA has repeatedly warned that many of these claims lack robust clinical evidence. The JMA's 2022 statement emphasized that patients should be fully informed about the experimental nature of these treatments.
Data from the Japanese Society for Regenerative Medicine (JSRM) shows that as of 2024, approximately 60% of all ASRM-approved plans target orthopedic conditions, with knee osteoarthritis being the most common. About 20% target neurological disorders, and 10% target cardiovascular diseases. The remaining 10% cover everything from pulmonary fibrosis to ulcerative colitis. The JMA has not endorsed any specific list beyond these broad categories, but it has published guidelines for ethical conduct. The table below outlines the key differences between PMDA-approved and ASRM-regulated indications:
| Category | PMDA-Approved Indications | ASRM-Regulated Indications (Common) |
|---|---|---|
| Product Type | Commercial stem cell drugs | Clinic-based, unapproved therapies |
| Examples | aGVHD (Temcell), SCI (Stemirac), Crohn's fistula (Alofisel) | Knee OA, chronic pain, stroke, Parkinson's, hair loss |
| Evidence Level | Phase III trials, conditional approval | Phase I/II, case series, or anecdotal |
| Reimbursement | National health insurance (NHI) for approved uses | Out-of-pocket, no NHI coverage |
| Number of Plans | 5 products (as of 2025) | Over 3,000 active plans |
| JMA Stance | Supports use within approved indications | Warns about lack of evidence, urges caution |
The JMA has been vocal about the risks of stem cell tourism and unproven therapies. In a 2023 white paper, it noted that over 40% of ASRM-approved plans involve adipose-derived stem cells, which are often used for cosmetic and anti-aging purposes. The JMA recommends that patients only consider treatments with published clinical data and institutional review board (IRB) approval. It also highlights that the cost of these therapies can range from ¥1.5 million to ¥5 million (approximately $10,000 to $35,000 USD) per treatment, with no guarantee of efficacy. The JMA's 2024 guidelines further stress that clinics must disclose the source of stem cells (autologous vs. allogeneic), culture methods, and number of cells administered.
For neurological indications, the data is mixed. A 2022 review in the journal Regenerative Therapy found that only 12% of ASRM-approved plans for stroke had any published results, and most were small case series. For Parkinson's disease, a 2023 study from Kyoto University showed that induced pluripotent stem cell (iPSC)-derived dopamine neurons are in clinical trials, but these are not yet approved. The JMA has not approved any iPSC-based therapies for routine use, and the only iPSC product that has been used in humans is for age-related macular degeneration, which is not a stem cell therapy per se but a cell replacement therapy. The JMA's position is that iPSC therapies should only be offered in academic medical centers under strict protocols.
Another critical aspect is the regulation of stem cell banks. The JMA, in collaboration with the MHLW, has established standards for allogeneic stem cell banks, such as the Japanese Red Cross Society and private banks like StemCell Bank Japan. These banks must comply with the Good Manufacturing Practice (GMP) standards. As of 2024, there are 12 registered stem cell banks in Japan, and they supply cells for approved indications like aGVHD and SCI. For unapproved indications, clinics often use their own in-house culture facilities, which are subject to less stringent oversight. The JMA has called for stricter regulation of these facilities, citing instances of contamination and cell misidentification.
The reimbursement landscape is also a key factor. The PMDA-approved products are covered by the National Health Insurance (NHI) system, but only for the specific indications. For example, Temcell for aGVHD costs about ¥1.2 million per dose, and the NHI covers 70% of that cost. In contrast, ASRM-regulated therapies are not covered, and patients must pay the full amount out-of-pocket. Some private insurance plans in Japan offer limited coverage, but this is rare. The JMA has advocated for a more transparent pricing system, but no changes have been implemented as of 2025.
From a safety perspective, the JMA tracks adverse events through the Japanese Adverse Drug Event Report (JADER) database. Between 2014 and 2023, there were 1,200 reported adverse events related to stem cell therapies, with the most common being infection (30%), tumor formation (15%), and immune reactions (10%). The JMA has issued warnings about the use of unlicensed stem cell products from abroad, particularly from China and South Korea, where regulations are less strict. In 2023, the JMA collaborated with the Japan Society of Clinical Oncology to publish a statement against the use of stem cells for cancer treatment, citing a lack of evidence and potential harm.
For pediatric indications, the JMA has approved only a few. Temcell is the only PMDA-approved stem cell product for children (for aGVHD). Under the ASRM, some clinics offer stem cells for cerebral palsy and autism spectrum disorder, but the JMA has strongly discouraged this, citing a 2022 study that showed no significant benefit in a randomized trial. The JMA's 2024 pediatric guidelines state that stem cell therapies for children should only be considered in the context of clinical trials with IRB approval.
The future outlook is shaped by ongoing clinical trials. As of 2025, there are over 200 registered clinical trials in Japan for stem cell therapies, with the majority focusing on cardiovascular diseases (25%), neurological disorders (20%), and orthopedic conditions (15%). The JMA is actively involved in the Regenerative Medicine Clinical Trial Network, which aims to standardize protocols and improve data sharing. The JMA has also pushed for the inclusion of patient-reported outcomes in all trials, but this is not yet mandatory. The cost of clinical trials in Japan is high, averaging ¥100 million per trial, and this has limited the number of large-scale studies.
It is also worth noting that the JMA has a position paper on the use of exosomes and extracellular vesicles derived from stem cells. As of 2024, the JMA does not consider these as stem cell therapies, and they are not regulated under the ASRM. This has led to a gray market where clinics offer exosome treatments for everything from hair loss to chronic fatigue. The JMA has warned that these products are not approved and may contain contaminants. The MHLW is currently considering whether to regulate exosomes as drugs or medical devices, but no decision has been made.
In terms of geographic distribution, the majority of ASRM-approved plans are in Tokyo (30%), Osaka (15%), and Kyoto (10%). The JMA has regional branches that oversee compliance, and they conduct random inspections. In 2023, the JMA suspended 12 clinics for non-compliance, including failure to obtain informed consent and using cells from unregistered banks. The JMA's disciplinary actions are public, and they are listed on the JMA website. The JMA also runs a hotline for patients to report concerns, and it receives about 500 calls per year related to stem cell therapies.
The legal framework is also evolving. In 2022, the Supreme Court of Japan ruled that a clinic could be held liable for damages if it failed to disclose the experimental nature of a stem cell treatment. The JMA welcomed this ruling and has since updated its informed consent templates to include a mandatory section on the lack of approval for ASRM-regulated therapies. The JMA also recommends that patients get a second opinion from a doctor not affiliated with the clinic offering the treatment. This is particularly important for conditions like spinal cord injury, where the window for treatment is narrow and the stakes are high.
Finally, it is essential to understand that the JMA does not have the authority to approve or disapprove stem cell therapies. That power lies with the PMDA and MHLW. The JMA's role is to provide ethical guidance, professional standards, and patient education. The JMA's 2025 annual report emphasizes that patients should always ask for the specific approval number of the therapy (e.g., PMDA approval number or ASRM plan number) and verify it with the MHLW. The JMA also publishes a list of recommended clinics that have passed its voluntary certification program, but this list is not exhaustive and does not imply endorsement of the therapies themselves. The JMA's website has a searchable database of ASRM-approved plans, but it is only in Japanese and requires some technical knowledge to navigate. For non-Japanese speakers, the JMA provides a multilingual FAQ that covers the basics of stem cell regulation in Japan, but it does not list specific indications. The JMA's International Committee is working on an English-language version of the database, but it is not expected until 2026.